RxDoctor Payments Data

William Bickers, MD

Pain Medicine · Milton, FLNPI 1114311073

Payments from drug & device makers

$5,066in general payments, 2019–2025

Across 90 payments — averaging $56.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Saluda Medical Americas, Inc.$2K
  • Nevro Corp.$900
  • Boston Scientific$468
  • Medtronic$399
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$364
  • Abbott$167
  • plus $690 from 11 others

What the payments were for

  • Travel & lodging$1,59231%
  • Food & beverage$3,47369%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,066 in reported general payments places this provider in the 65th percentile of 596 pain medicine providers in Florida.

See all pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$117,168
Medicare patients
271
Services billed
1,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen852$14,683
Pregabalin362$13,584
MovantikNaloxegol Oxalate25$10,112
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen358$7,825
Xtampza ErOxycodone Myristate21$7,800
BelbucaBuprenorphine Hcl15$5,788
Gabapentin506$4,238
Oxycodone Hcl161$3,560
Celecoxib93$3,114
Fentanyl21$2,792
Morphine Sulfate ErMorphine Sulfate122$2,586
Tizanidine Hcl112$1,965
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl19$1,774
Duloxetine Hcl87$1,616
Tramadol Hcl183$1,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$84$13,58836 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate$68$2,17544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 596 pain medicine providers in Florida.

Other pain medicine in Milton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →